Renaissance Technologies LLC Increases Stake in Achieve Life Sciences Inc (NASDAQ:ACHV)

Renaissance Technologies LLC grew its position in shares of Achieve Life Sciences Inc (NASDAQ:ACHV) by 12.5% in the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 321,268 shares of the biopharmaceutical company’s stock after buying an additional 35,607 shares during the quarter. Renaissance Technologies LLC owned 3.97% of Achieve Life Sciences worth $620,000 as of its most recent filing with the SEC.

Separately, Searle & CO. raised its position in Achieve Life Sciences by 80.4% during the 2nd quarter. Searle & CO. now owns 132,592 shares of the biopharmaceutical company’s stock worth $256,000 after buying an additional 59,092 shares during the last quarter. 18.63% of the stock is currently owned by institutional investors and hedge funds.

Shares of Achieve Life Sciences stock opened at $1.58 on Friday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 3.62 and a current ratio of 3.62. Achieve Life Sciences Inc has a one year low of $1.04 and a one year high of $4.63. The firm has a fifty day moving average of $1.99 and a two-hundred day moving average of $2.69.

Achieve Life Sciences (NASDAQ:ACHV) last announced its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.33) by ($0.17). On average, equities research analysts forecast that Achieve Life Sciences Inc will post -1.6 earnings per share for the current fiscal year.

A number of brokerages have commented on ACHV. Maxim Group restated a “buy” rating and set a $6.00 price objective on shares of Achieve Life Sciences in a research report on Tuesday, October 1st. LADENBURG THALM/SH SH restated a “buy” rating and set a $20.00 price objective on shares of Achieve Life Sciences in a research report on Friday, August 9th. Finally, ValuEngine upgraded shares of Achieve Life Sciences from a “hold” rating to a “buy” rating in a research report on Wednesday, October 2nd.

Achieve Life Sciences Company Profile

Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes smoking cessation aids in the United States and internationally. The company offers Cytisine, a plant-based alkaloid that interacts with nicotine receptors in the brain to help reduce the severity of nicotine withdrawal symptoms.

Further Reading: What member countries make up the G-20?

Want to see what other hedge funds are holding ACHV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Achieve Life Sciences Inc (NASDAQ:ACHV).

Institutional Ownership by Quarter for Achieve Life Sciences (NASDAQ:ACHV)

Receive News & Ratings for Achieve Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achieve Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.